Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rBet v1-FV
- Development stage
- Phase 2
- Lead developer
- Allergopharma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous[9]
01
Overview
rBet v1-FV is a hypoallergenic, recombinant folding variant of the major birch pollen allergen Bet v 1. It is designed for use in allergen immunotherapy (AIT) to treat patients with IgE-mediated seasonal allergic rhinoconjunctivitis due to birch pollen allergy. The drug works by exposing the immune system to a modified form of the allergen, aiming to induce tolerance and reduce allergic symptoms during birch pollen season. Compared with native extracts, rBet v1-FV can be administered at higher doses without increased adverse effects and induces significant increases in specific IgG subclasses (IgG1 and IgG4), reflecting an immunomodulatory effect. Clinical trials have shown that it reduces symptom scores and is well tolerated[2][6][9].
- Brand names
- rBet v1-FV
- Other names
- recombinant birch pollen allergoid (folding variant)recombinant hypoallergenic derivative of Bet v 1folding variant of recombinant Bet v 1
02
Targets
Bet v 1-sIgE (Bet v 1-specific IgE)Bet v 1
Beyond the preview
Go deeper on rBet v1-FV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rBet v1-FV.